CompanyGraph
Suzhou Novoprotein Scientific Co., Ltd.
688137 · SSE · China
novoprotein.com.cnFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $22.34M, lower than 95% of all stocks globally
- PositionCurrent ratio is 23.22×, higher than 95% of its Biotechnology peers (median 5.76×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
5.66BCNY842.09M · vs all stocks (USD)
Revenue (TTM)
150.24MCNY22.34M · vs all stocks (USD)
Profit Margin
-50.97%vs Biotechnology peers
Beta
1.40xvs all stocks
52-Week Change
78.00%vs all stocks
Market Capitalization
5.66BCNY842.09M · vs all stocks (USD)
Enterprise Value
3.98BCNY591.87M · vs all stocks (USD)
Price to Sales (TTM)
37.69xvs Biotechnology peers
Price to Book (MRQ)
2.79xvs Biotechnology peers
Enterprise to Revenue
26.49xvs Biotechnology peers
Enterprise to EBITDA
-52.55xvs Biotechnology peers
Gross Margin
70.29%vs Biotechnology peers
Profit Margin
-50.97%vs Biotechnology peers
Operating Margin
-32.83%vs Biotechnology peers
Return on Assets (TTM)
-2.55%vs Biotechnology peers
Return on Equity (TTM)
-3.72%vs Biotechnology peers
Revenue (TTM)
150.24MCNY22.34M · vs all stocks (USD)
Revenue per Share (TTM)
2.13CNYUpdated Aug 21, 2026Quarterly Revenue Growth
11.40%vs Biotechnology peers
Gross Profit (TTM)
76.61MCNY11.39M · vs all stocks (USD)
EBITDA (TTM)
-75.74MCNY-11.26M · vs all stocks (USD)
Net Income (TTM)
-76.58MCNY-11.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.99%vs Biotechnology peers
Operating Cash Flow (TTM)
-14.17MCNY-2.11M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
146.44MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
48.15MCNYFY2025 · Dec 31, 2025Gross Profit
98.29MCNYFY2025 · Dec 31, 2025Operating Income
-66.69MCNY-9.92M · vs all stocks (USD)
Pre-tax Income
-70.37MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.41MCNYFY2025 · Dec 31, 2025Net Income
-77.78MCNYFY2025 · Dec 31, 2025EBIT
-67.83MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-6.71MCNYFY2025 · Dec 31, 2025Research & Development
64.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.50MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.54MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.11CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.11CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
70.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
70.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-77.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-101.26MCNYFY2025 · Dec 31, 2025Free Cash Flow
-180.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
710.81MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-77.78MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-19.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.22MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-78.89MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.57BCNYFY2025 · Dec 31, 2025Sale of Investments
2.75BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
102.14MCNYFY2025 · Dec 31, 2025Other Financing Charges
-23.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
70.18MSharesUpdated Aug 21, 2026Float Shares
22.03MSharesUpdated Aug 21, 2026% Held by Insiders
68.11%vs all stocks
% Held by Institutions
4.29%vs all stocks
Total Cash (MRQ)
772.94MCNY114.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.10CNYUpdated Aug 21, 2026Total Debt (MRQ)
52.55MCNY7.81M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0260xvs Biotechnology peers
Current Ratio (MRQ)
23.22xvs Biotechnology peers
Book Value per Share (MRQ)
29.02CNYUpdated Aug 21, 2026Total Assets
2.15BCNY319.96M · vs all stocks (USD)
Total Current Assets
1.85BCNYFY2025 · Dec 31, 2025Total Liabilities
116.83MCNYFY2025 · Dec 31, 2025Total Non-current Assets
296.58MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
47.70MCNYFY2025 · Dec 31, 2025Total Current Liabilities
69.12MCNYFY2025 · Dec 31, 2025Cash
711.10MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.31KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
711.10MCNYFY2025 · Dec 31, 2025Accounts Receivable
61.77MCNYFY2025 · Dec 31, 2025Inventory
63.32MCNYFY2025 · Dec 31, 2025Accounts Payable
36.23MCNYFY2025 · Dec 31, 2025Short-term Debt
9.48MCNYFY2025 · Dec 31, 2025Other Current Liabilities
777.57KCNYFY2025 · Dec 31, 2025Long-term Debt
45.60MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
551.14KCNYFY2025 · Dec 31, 2025Common Stock (Book)
70.18MCNYFY2025 · Dec 31, 2025Retained Earnings
-17.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.03BCNY302.58M · vs all stocks (USD)
Treasury Stock
11.96MCNYFY2025 · Dec 31, 202552-Week Low
33.20CNYUpdated Aug 21, 202652-Week High
80.99CNYUpdated Aug 21, 202652-Week Change
78.00%vs all stocks
Beta
1.40xvs all stocks
50-Day MA
41.33CNYUpdated Aug 21, 2026200-Day MA
43.15CNYUpdated Aug 21, 2026Avg 10-Day Volume
7.22MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.28MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.09CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 23.22×, higher than 95% of its Biotechnology peers (median 5.76×)Significant
Current ratio: 23.22Industry median: 5.76Industry P95: 22.23Peers compared: 258
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.11Receivables vs revenue divergence: 10.44
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $22.34M, lower than 95% of all stocks globallySignificant
Revenue (USD): 22,342,430.715Global P5: 32,166,921.735
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang International Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hyliion Holdings Corp.
3 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Der Future Science & Technology Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Xingjiang Bai Hua Cun Pharmaceutical Co. Ltd.
1 interpretationLow-Leverage Liquidity Configuration